CXCL9 and neoplasm: CD103+ DCs are usually necessary to recruit CD8+ T cells through CXCL9; failure to promote their recruitment in patients of β-catenin high tumors renders these resistant to anti-PD-1 blockade therapy or abrogate treatment effects of ACT in murine tumor models [78,79].